Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$155.29 USD

155.29
1,094,683

+0.46 (0.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $155.34 +0.05 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?

Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Quest Diagnostics (DGX) Rides on Test Sales, Base Volume Gain

Quest Diagnostics (DGX) continues to benefit from rapidly increasing molecular diagnostic testing volumes, driven by the massive spread of the new COVID-19 variant.

The Zacks Analyst Blog Highlights: Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics and Quidel Corp.

Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics,and Quidel Corp. are highlighted in this analyst blog.

Riya Anand headshot

3 Diagnostics Stocks in Focus Amid the Omicron Outbreak

Stocks like Thermo Fisher (TMO), QIAGEN (QGEN) and Quidel (QDEL) are expected to gain from increasing testing demand.

Trina Mukherjee headshot

Forget DaVita (DVA), Buy These 3 Lucrative Medical Care Stocks

With stocks offering dialysis services, including DaVita (DVA), facing several issues, it would be prudent to invest in medical care and services stocks like DGX, AMN and CODX instead for 2022.

Quest Diagnostics (DGX) is an Incredible Growth Stock: 3 Reasons Why

Quest Diagnostics (DGX) could produce exceptional returns because of its solid growth attributes.

Has Quest Diagnostics (DGX) Outpaced Other Medical Stocks This Year?

Here is how Quest Diagnostics (DGX) and LabCorp (LH) have performed compared to their sector so far this year.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.

Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?

Robust performance of the base business and COVID-19 testing volume gains are driving the top line for Quest Diagnostics (DGX).

Quest Diagnostics (DGX) Expands Testing Suite With NGS Test

Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.

Urmimala Biswas headshot

Quest Diagnostics' (DGX) COVID-19 Testing Demand Up in 3 Weeks

According to Quest Diagnostics (DGX), as the nation is entering the holiday season, the importance of testing service is gaining more importance with regard to minimizing the risk of community exposure of COVID-19.

LabCorp (LH) Q3 Earnings Surpass Estimates, 2021 View Up

LabCorp's (LH) Q3 Diagnostics revenues get significantly impacted by drop in sales for COVID-19 testing.

Urmimala Biswas headshot

4 Medical Products Stocks Poised to Beat This Earnings Season

Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.

CONMED's (CNMD) Q3 Earnings Beat Estimates, Revenues Miss

CONMED's (CNMD) third-quarter earnings reflect strong segmental performance.

West Pharmaceutical (WST) Q3 Earnings & Revenues Beat Estimates

West Pharmaceutical's (WST) third-quarter earnings reflect segmental strong performance.

Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates

Baxter's (BAX) third-quarter results reflect robust performance across all its business units.

Align Technology (ALGN) Q3 Earnings Top Estimates, Margins Up

Continued momentum in Invisalign Clear Aligners and iTero scanners sales volumes drove Align Technology's (ALGN) revenues during the third quarter.

Edwards Lifesciences (EW) Beats on Q3 Earnings, Gross Margin Up

Strong sales growth across all four products group along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) third-quarter revenues.

Abiomed (ABMD) Beats on Q2 Earnings, Lowers FY22 Guidance

Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.

Thermo Fisher (TMO) Beats on Q3 Earnings, Raises 2021 View

Thermo Fisher (TMO) delivers a strong quarterly performance, leveraging on a significant rebound in its base business.

Boston Scientific (BSX) Q3 Earnings Top Estimates, Margins Up

Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.

Masimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up

Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q3 sales.

Zacks.com featured highlights include: Olin, Quest Diagnostics, Equinor ASA, Teck Resources and Goldman Sachs

Zacks.com featured highlights include: Olin, Quest Diagnostics, Equinor ASA, Teck Resources and Goldman Sachs

Ecolab (ECL) Q3 Earnings & Revenues Beat Mark, Margins Down

Ecolab's (ECL) robust performance across the majority of its segments drives its Q3 sales despite pandemic-led business challenges.

Is Quest Diagnostics (DGX) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.